JNJ · 10-Q · 2026Q2 · Full report
Orthopaedics Separation
JOHNSON & JOHNSON · 2026-07-23 · Importance 46 · Surprise 42 · In source text
Johnson & Johnson announced in October 2025 that it intended to separate its Orthopaedics business. The Company continues to evaluate multiple paths for the separation and targets completion within 18 to 24 months of the announcement. Separation-related costs were $0.4 billion in the fiscal six months of 2026 and $0.3 billion in the second quarter, reducing MedTech segment profitability.
Key facts
- The Company announced in October 2025 its intention to separate its Orthopaedics business and continues to explore multiple paths with a targeted completion within 18 to 24 months after the initial announcement. source
- Other (income) expense, net line item includes orthopaedics separation related expense of $0.4 billion in fiscal six months of 2026. source
- Other (income) expense, net for the fiscal second quarter of 2026 includes orthopaedics separation related expense of $0.2 billion. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | unclear | probable | — | The Company announced in October 2025 its intention to separate its Orthopaedics business and continues to explore multiple paths with a… |